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conditions were more frequent in parents with NEs related to work or friends. 
CONCLUSIONS: PWH with one NE were more likely to report other NEs. 
PWH/parents with NEs reported greater social worker involvement and 
treatment for psychological conditions. Further studies are needed to assess 
temporal relationships between NEs and HTC visits/advice, and support the 
relevance of timely social work and psychological counselling in comprehensive 
care.  
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OBJECTIVES: Pain is not a disease, but might be a symptom of a disease, the 
effect of a disease or an accident. It pervades a person’s daily life activities, social 
interaction and productive hours. It has powerful psychological and social 
consequences. In Russia, there are no solid estimates of the magnitude of the 
condition. This study is aimed to assess co-morbidity, quality of life (QOL), 
work/productivity loss, and resource utilization in Russian urban adults with 
pain. METHODS: Patients’ self-reported data were collected from 2011 National 
Health and Wellness Survey (NHWS). Survey represented major urban areas in 
Russia. QOL was measured by the physical (PCS) and mental (MCS) component 
summary scores of the (SF-12v2). Loss of work/productivity was measured by the 
Work Productivity and Activity Impairment instrument. Medical resource 
utilization was measured by health care provider, ambulance request and 
hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 
2,670 (28%) reported to experience pain over the past month (17% mild, 54% 
moderate and 28% severe) – 35% not receiving medication at all. Average age of 
patients experiencing pain was 41.5 years. Pain group reported more co-
morbidities (headaches 77%, sleep difficulties 54%, insomnia 47%, heartburn 45%, 
depression 39%, high blood pressure 33%), lower mean scores of PCS (43.4 
vs.47.8) and MCS (40.0 vs. 45.0), more patients visited health care providers (83% 
vs. 67%), and a higher percentage were hospitalized (13% vs. 8%) over the past 6 
months compared to no experiencing pain group. Furthermore, pain group 
reported 35.9% impairment in daily activity compared to 23.0% in no 
experiencing pain group. All mentioned differences were statistically significant 
(p < 0.05) and all percentages or means are projected values. CONCLUSIONS: 
From Russian NHWS results, patients experiencing pain suffer from impairment 
in QOL, work/productivity loss and more co-morbidities. Findings indicate there 
is still an unmet medical need in Russian patients with pain.  
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OBJECTIVES: The occurrence of obesity in the UK is rapidly increasing, and is 
associated with significant health problems and economic costs. Despite this, 
there is currently only one drug recommended by NICE for the treatment of 
obesity. The purpose of the study was to examine whether the clinical 
development of obesity treatments is keeping up with the increasing obese 
population in the UK. METHODS: Adult obesity prevalence data for England were 
obtained from the 2011 Health Survey for England Trend Tables. Total economic 
costs were obtained from the National Obesity Observatory. ClinicalTrials.gov 
was searched for the number of clinical trials investigating drug and device 
interventions for obesity initiated yearly from database inception to the 17th of 
January 2013. Results were reviewed to exclude trials investigating dietary 
supplements, behavioural changes, dietary changes, and those without a UK 
centre. RESULTS: The prevalence of obese adults in England has risen from 
14.9% (1993) to 24.8% (2011). This has been associated with an estimated increase 
in total costs to the UK of £2.6 billion (1998) to £15.8 billion (2007). Since 2000, 46 
trials have been initiated investigating treatments for obesity. The number of 
clinical trials initiated yearly has increased since 2000; however recent years 
have seen a decline. 1 trial was initiated in 2000, generally increasing up until 
2010 when 8 trials were initiated. 2011 and 2012 both saw a dip in the number of 
initiated trials, with only 3 trials started in 2012. CONCLUSIONS: The prevalence 
and economic burden of obesity has increased drastically in the UK over the past 
18 years. The rate of clinical development has also increased; however, this rate 
is low in relation to the significance of this health problem and the increase in 
the obese population. These results highlight the need for further clinical 
development in treating obesity.  
 
PSY91  
IMPACTS OF BLACK BOX WARNING, NATIONAL COVERAGE DETERMINATION, 
AND RISK EVALUATION AND MITIGATION STRATEGIES ON THE INPATIENT 
ON-LABEL AND OFF-LABEL USE OF ERYTHROPOIESIS-STIMULATING AGENTS  
Seetasith A, Holdford DA 
Virginia Commonwealth University, Richmond, VA, USA  
OBJECTIVES: This study aims to quantify the impact of (1) black box warning, (2) 
CMS National Coverage Determination (NCD), and (3) Risk Evaluation and 
Mitigation Strategies (REMS) on erythropoiesis-stimulating agents (ESAs) on-label 
and off-label utilization patterns among adult inpatients. METHODS: Electronic 
health records in Cerner HealthFact database from January 2005 to June 2011 
were used. Eligible patients for ESA prescribing were categorized using ICD-9-CM 
codes and medication information. The three patient categories were (1) on-label 
(ONS, conditions approved by the FDA); (2) off-label supported (OFS, strong 
clinical evidence for use in unapproved indications); and (3) off-label 
unsupported (OFU, low/no evidence supporting use in unapproved indications). 
The likelihood of receiving ESAs was assessed using a generalized estimating 
equation approach with binary logistic regression technique, clustering for 
hospitals, and controlling for potential confounders. RESULTS: We identified 
730,421 patients with ONS conditions (33,004 users, 4.5%), 505, 658 with OFS 
conditions (5,140 users, 1.0%), and 558,917 patients with OFU conditions (4,491 
users, 0.8%). Black box warning and REMS had no impact on the odds of receiving 
ESAs. There was a significant decline in all three use categories the month 
following NCD. ONS patients were 13% less likely to receive ESAs (OR 0.867, 95% 
CI 0.762, 0.986, p = 0.0299). OFS patients were 20% less likely (OR 0.799, 95% CI 
0.716, 0.891, p < 0.0001) and OFU patients were 38% less likely to receive ESAs (OR 
0.622, 95% CI 0.474, 0.817, p = 0.0006). Age, gender, race, source of payment, 
admission type, clinical complexity, discharge disposition, and hospital size were 
significantly associated with on-label and off-label use. CONCLUSIONS: We 
demonstrated the relative impact of three safety interventions on on-label and 
off-label ESA use in the hospital settings. Reimbursement change may have 
unintentionally reduced the likelihood of receiving ESAs in patients who could 
have otherwise benefited.  
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OBJECTIVES: Escalating rates of prescription opioid use and abuse have occurred 
in the context of efforts to improve the identification and management of non-
malignant pain. To characterize the diagnosis and management of non-
malignant pain in ambulatory, office-based settings between 2000 and 2010. 
METHODS: Serial cross-sectional and multivariate regression analyses of the 
National Ambulatory Medical Care Survey (NAMCS), a nationally representative 
audit of office-based physician visits. The main outcome measures were 1) 
Annual volume of visits among adults with a primary symptom or diagnosis of 
pain, and 2) prescription opioid and non-opioid pharmacologic therapy in visits 
limited to new musculoskeletal pain. RESULTS: Primary symptoms or diagnoses 
of pain consistently represented one-fifth of visits, varying less than 2% from 
2000 through 2010. Patient-reported pain comprised 17% to 19% of visits, 
whereas provider diagnoses of pain increased nearly 50% from 2000 (5.7% of 
visits with pain as a primary diagnosis) to 2010 (8.5%). Among all pain visits, 
opioid use nearly doubled from 11.3% to 19.6%, whereas use of non-opioid 
analgesics remained unchanged (26%-29% of visits). Pain medications were 
associated with one-half of new musculoskeletal pain visits, with the use of non-
opioid pharmacotherapies decreasing from 38% of visits (2000) to 29% of visits 
(2010). After adjusting for potentially confounding covariates, few patient, 
physician or practice characteristics were associated with the use of non-opioid 
rather than opioid analgesia. CONCLUSIONS: Increased opioid use during the 
past decade has not been accompanied by similar increases in non-opioid 
analgesics. Clinical alternatives to prescription opioids may be underutilized as a 
means of treating ambulatory non-malignant pain.  
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OBJECTIVES: Glomerular filtration rate (GFR) is known to better estimate renal 
function than serum creatinine (SCr), but SCr is commonly used when screening 
patients for inclusion into clinical trials of the nephrotoxic drug cisplatin. The 
objective of this meta-analysis was to indirectly compare incidence of 
nephrotoxicity in trials including cisplatin when renal function was assessed 
using either SCr or GFR for eligibility criteria. METHODS: A PubMed literature 
search identified randomized trials comparing cisplatin to non-cisplatin 
regimens. Included studies were performed from 1990-2010, used SCr or GFR as 
inclusion criteria, and reported incidence of WHO grade ≥3 nephrotoxic events 
for both treatment arms. Review articles, observational studies, phase 1 studies, 
non-randomized trials, studies without a comparator group, or studies not 
reported in English were excluded. Inverse variance weighted fixed effects (FE) 
and random effects (RE) methods were used to estimate the relative risk (RR) 
associated with cisplatin versus non-cisplatin regimens with sub-group analyses 
of studies using SCr, GFR, and either SCr or GFR for screening. RESULTS: A total 
of 2,359 studies were identified from the literature search and 29 studies met all 
inclusion and exclusion criteria (N=6,146 patients). Of these, 18 studies used SCr 
(N=4,146), 5 used GFR (N=993), and 6 used SCr or GFR (N=1,007) for screening. The 
overall RR for developing nephrotoxicity with cisplatin versus non-cisplatin 
treatment was 2.09 (95%CI 1.33-3.27, p=0.001). In sub-group analyses, the RR was 
2.47 (95%CI 1.24-4.94, p=0.011) for SCr, 1.84 (95%CI 0.96-3.54, p=0.067) for GFR, and 
1.88 (95%CI 0.49-7.26, p=0.359) for either SCr or GFR. Results did not vary between 
